HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Betzana Zambrano Selected Research

Dengue Vaccines

1/2022Immunogenicity and safety of booster CYD-TDV dengue vaccine after alternative primary vaccination schedules in healthy individuals aged 9-50 years: a randomised, controlled, phase 2, non-inferiority study.
1/2021Immunogenicity and safety of simplified vaccination schedules for the CYD-TDV dengue vaccine in healthy individuals aged 9-50 years (CYD65): a randomised, controlled, phase 2, non-inferiority study.
1/2021Zika and Dengue Interactions in the Context of a Large Dengue Vaccine Clinical Trial in Latin America.
1/2021Analysis of Hospitalized and Severe Dengue Cases Over the 6 years of Follow-up of the Tetravalent Dengue Vaccine (CYD-TDV) Efficacy Trials in Asia and Latin America.
1/2020Efficacy after 1 and 2 doses of CYD-TDV in dengue endemic areas by dengue serostatus.
1/2020Secondary Analysis of the Efficacy and Safety Trial Data of the Tetravalent Dengue Vaccine in Children and Adolescents in Colombia.
7/2018Effect of Dengue Serostatus on Dengue Vaccine Safety and Efficacy.
1/2018Dengue seroprevalence: data from the clinical development of a tetravalent dengue vaccine in 14 countries (2005-2014).
3/2016Symptomatic Dengue in Children in 10 Asian and Latin American Countries.
7/2015Prospective cohort study with active surveillance for fever in four dengue endemic countries in Latin America.
For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Betzana Zambrano Research Topics

Disease

19Dengue (Dengue Fever)
01/2022 - 01/2011
6Hepatitis B
11/2017 - 04/2010
6Tetanus
11/2017 - 09/2003
5Whooping Cough (Pertussis)
11/2017 - 09/2003
5Diphtheria
11/2017 - 06/2011
4Infections
01/2021 - 01/2015
2Severe Dengue
01/2021 - 09/2015
2Poliomyelitis (Polio)
11/2017 - 09/2003
1Diarrhea
01/2015
1Japanese Encephalitis
01/2014
1Yellow Fever
09/2012
1Myalgia
01/2011
1Pain (Aches)
01/2011
1Headache (Headaches)
01/2011

Drug/Important Bio-Agent (IBA)

16VaccinesIBA
01/2021 - 09/2003
13Dengue VaccinesIBA
01/2022 - 01/2011
5Neutralizing AntibodiesIBA
01/2021 - 09/2012
5Haemophilus influenza type b polysaccharide vaccine-tetanus toxin conjugate (ActHIB)IBA
11/2017 - 06/2011
3AntigensIBA
07/2015 - 08/2012
3Combined VaccinesIBA
08/2012 - 04/2010
2Immunoglobulin G (IgG)IBA
01/2021 - 07/2018
2Proteins (Proteins, Gene)FDA Link
01/2021 - 07/2018
2Pertussis VaccineIBA
10/2013 - 08/2012
2Hemagglutinins (Hemagglutinin)IBA
10/2012 - 01/2012
1CYD-TDV vaccineIBA
01/2019
1EnzymesIBA
07/2018
1ImmunosorbentsIBA
07/2018
1AntipyreticsIBA
11/2017
1Anti-Bacterial Agents (Antibiotics)IBA
01/2015
1DNA Restriction Enzymes (Restriction Endonuclease)IBA
01/2015
1ChimeriVaxIBA
01/2014
1Pertussis ToxinIBA
10/2012
1antineoplaston A10 (A 10)IBA
09/2012
1pertussis toxoidIBA
01/2012
1Phosphates (Orthophosphate)IBA
01/2012
1RibitolIBA
01/2012
1PentavacIBA
06/2011
1Surface Antigens (Surface Antigen)IBA
06/2011
1DTaP-IPV-HB-PRP-T vaccineIBA
06/2011
1Hepatitis A Vaccines (Hepatitis A Vaccine)IBA
09/2003

Therapy/Procedure

3Injections
10/2016 - 01/2011